KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

EBioMedicine · 2024-Dec · PMID 39631145

Panel F质量警告待 EXE 对齐验证

Progression-free survival

Fig. 2 Outcomes based on baseline FDG-PET staging, period, and rituximab. Progression-free survival by ITT analysis of IFRT+(R)CVP vs. IFRT arms in the A) late-era and B) early era. C) Progression-free survival in all patients in the TROG99.03 trial based on whether baseline FDG-PET was used as a staging modality and D) FDG-PET staged patients by IIT analysis of IFRT+(R)CVP vs. IFRT arms. E) Progression-free survival, per treatment received, of R–CVP treated patients compared with all non-rituximab containing treatments. F) Progression-free survival, per treatment received, of R–CVP treated patients compared with CVP treated patients.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.50
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:34:16+00:00